|Bid||11.93 x 1100|
|Ask||11.94 x 900|
|Day's range||11.91 - 12.51|
|52-week range||10.76 - 94.17|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||20.73|
|Earnings date||12 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||16.67|
Taylor Carmichael (Novavax): Novavax's COVID-19 vaccine is still not on the market anywhere, which has made the stock a real wild ride for investors. The vaccine specialist started off 2020 so small it almost qualified as a micro-cap, with its stock priced at $4 a share. When COVID-19 hit, however, the stock took off.
This month, as Merck (NYSE: MRK) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19, Atea Pharmaceuticals (NASDAQ: AVIR) stock saw a significant drop. Unfortunately, investors are unlikely to see the small-cap biotech replicate Moderna's success as the next COVID-19 underdog success story after news of its negative clinical trial. Let's explore what caused Atea's drop and how biotech investors should examine their future investments.
Biotech stocks are in a slump. Despite numerous wins in the high-profile areas of COVID-19 and cancer therapy, the industry has failed to excite investors this year -- as seen in the 12% year-to-date fall in the the bellwether SPDR S&P Biotech ETF. Risk-tolerant growth investors appear to be favoring other vehicles over biotech in 2021, such as the red-hot cryptocurrency Shiba Inu (CRYPTO: SHIB), electric-vehicle giant Tesla (NASDAQ: TSLA), and emerging social media plays such as Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN).